Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GV20-0251 |
| Synonyms | |
| Therapy Description |
GV20-0251 is an antibody targeting IGSF8, which potentially enhances antitumor immune response and inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S187-S188). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GV20-0251 | GV20 0251|GV200251 | GV20-0251 is an antibody targeting IGSF8, which potentially enhances antitumor immune response and inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S187-S188). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05669430 | Phase I | GV20-0251 | A Study of GV20-0251 in Patients With Solid Tumor Malignancies | Recruiting | USA | 0 |